UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) December 11, 2006

SONUS PHARMACEUTICALS, INC.
(Exact name of Registrant as Specified in Its Charter)

Delaware	0-26866	95-4343413
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No)

22026 20th Avenue S.E., Bothell, Washington 98021
(Address of principal executive offices)

(425) 487-9500
(Registrant’s telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Compensatory Arrangements of Certain Officers

(e) At its regularly scheduled meeting on December 11, 2006, the Board of Directors of Sonus Pharmaceuticals, Inc. approved a new Compensation Policy and Executive Compensation Program which sets forth the policy and practices concerning executive compensation. The primary components of which include base salary, bonus and equity awards. These documents are attached as exhibits to this Form 8-K.

Item 9.01 Exhibits

(d)	Exhibit 10.1	Compensation Policy

	Exhibit 10.2	Executive Compensation Program

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SONUS PHARMACEUTICALS, INC.


Date: December 15, 2006	By:	/s/ Alan Fuhrman
			Alan Fuhrman
			Senior Vice President and Chief Financial Officer

EXHIBIT INDEX

Exhibit No.		Description

Exhibit 10.1		Compensation Policy

Exhibit 10.2		Executive Compensation Program